miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 19, 2026

The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond

View original at nasdaq.com
The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond Key Points AbbVie provides an attractive combination of income, value, and growth…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Enbridge has visible growth through the end of the decade, with roughly $50 billion of opportunities identified

    60% confidence

  • AbbVie should deliver solid growth over the next few years driven by drugs like Rinvoq and Skyrizi and promising late-stage pipeline programs

    60% confidence

  • The Federal Reserve is virtually paralyzed by uncertainty about inflation and the job market

    60% confidence

  • Now is a great time to invest in dividend stocks with above-average yields

    60% confidence

  • Realty Income has particularly promising opportunities in Europe, where the total addressable market is $8.5 trillion and competition is limited

    60% confidence

  • Enbridge expects to deliver growth across all aspects of its business, especially in natural gas transmission

    60% confidence

  • The 10 stocks identified by Stock Advisor could produce monster returns in the coming years

    60% confidence

Data points we hold from this source

S&P 500 · healthcare sector forward pe ratio17.4 ratio
S&P 500 · forward pe ratio20 ratio
AbbVie Inc. · dividend increase streak53 years
AbbVie Inc. · forward pe ratio14.3 ratio
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Best High-Yield Dividend Stocks to Buy for 2026 and Beyond — Source | Via News | es.VIA.NEWS